Realco S.A. Overview
Realco is a Belgian micro-cap biotechnology and green-chemistry manufacturer. It specialises in enzyme-based hygiene, with a particular focus on detecting, removing and preventing bacterial biofilms. Founded in 1968 as a water-treatment and cleaning supplier, it was rebuilt from 1991 by the Blackman family around enzymatic formulations and moved to the Louvain-la-Neuve Science Park in 1995. Today it formulates and manufactures about 230 active products. These serve four end-markets: the food and beverage industry (about 59% of FY2025 sales), food services and retail (24%), home care through its Ecocert-certified Eezym consumer brand (12%), and health/life sciences (5%). Products are sold with audit, monitoring and training services. Realco occupies a defensible niche: proprietary enzyme–biofilm know-how, a patent estate it has enforced in court, and documented customer outcomes such as shelf-life extension. However, it is sub-scale (EUR 13.8m turnover in FY2025), thinly traded, family-controlled, and exposed to its loss-making medical spin-off OneLife. That exposure drove a EUR 0.77m net loss in FY2025.
Company's own description
In its 2024 Annual Report, Realco describes itself as a company that develops, produces and markets hygiene products derived from green chemistry. It stresses technical and scientific support "from the factory to the kitchen", aimed at high performance, safety and sustainability. Its stated mission is to co-create high-performing solutions for the ecological transition. It defines four sectors of activity (2024 Annual Report, "Secteurs d'activités"):
Food industry: Farming, meat, dairy, micro-breweries and other processors, where Realco positions itself as an expert in bacterial decontamination that preserves freshness "from farm to fork".
Health: The Biosafety expertise pole serves pharmaceutical and cosmetics manufacturers (Life Sciences), while the biomedical spin-off OneLife addresses decontamination of medical devices and hospital environments.
Food services and retail: Restaurants, collective catering, butchers and food retail.
Home: The Eezym range of household products made with renewable, naturally derived ingredients ("#homedetox").
Business model and revenue model
Realco is a formulator-manufacturer. It buys enzymes (obtained by microbial fermentation from bacteria, yeasts or fungi), surfactants, Ecocert-compliant raw materials and packaging. It formulates and fills products at its rebuilt Louvain-la-Neuve plant and sells them:
-
Directly to industrial food processors, collective catering and healthcare/life-science sites, typically bundled with audit, protocol design, training (Realco Academy), monitoring and technical support. The 2024 report notes that spending on technical equipment and services for customer support roughly tripled versus 2019.
-
Through distributors and retail chains, for example specialised DIY and food-retail chains for Eezym, and distributors such as the REPA group catalogue for professional products. The 2024 report lists DIY and food retail chains among its customer channels.
-
Through subsidiaries. Realzyme LLC (US, 75%-owned, commercial only) buys from Realco and resells in North America. OneLife SA (33.85%) buys enzymatic products manufactured by Realco for the medical market.
Revenue-mix characterisation (analyst estimate, not company-disclosed): product sales are the overwhelming majority of revenue. Services (audits, biofilm treatment interventions, filtration performance programmes, training) are embedded in pricing or billed alongside products. There is no subscription or licensing revenue of note. The company also resells non-enzymatic disinfectants it does not manufacture (2024 Annual Report). It manufactured certain chemical products for Fluidra for four years after the 2021 pool-business sale (press release, 25 March 2021).
Value-chain position
Realco sits between industrial enzyme producers (upstream: global biotech suppliers) and end users. Its value-add is formulation IP (multi-enzyme synergies with green-chemistry surfactants), application know-how (biofilm sampling, detection and removal protocols; membrane-filtration audits), and regulatory dossiers (REACH/CLP, biocide registrations, Ecocert). It is not an enzyme producer. That makes it a price-taker on its key input, while its service intensity differentiates it from commodity detergent suppliers.
Customer types and end-markets
| End-market | Sub-segments named by company | Representative customer outcome (company-reported) |
|---|---|---|
| Food industry | Dairy, meat and fish, soft drinks, beer, bakery and confectionery, ready meals, plant-based | A meat-sector customer reported fresh-burger shelf life (DLC) extended from 11 to 23 days; a dairy customer improved membrane-filtration water flux (website testimonials) |
| Food services and retail | Restaurants, collective kitchens, retail, supermarkets | A central hospital kitchen replaced caustic soda-based products and reported reduced skin problems for staff (website) |
| Health | Life Sciences (pharma, cosmetics); medical devices via OneLife | Biofilm detection on surgical instruments (blue stain) plus enzymatic removal (OneLife) |
| Home | Eezym consumer range | Consumer testimonials (website) |
Independent characterisation
Realco is best understood as a niche specialty-chemicals SME with a biotech narrative. Its economics resemble a small industrial-hygiene supplier: labour cost is about 33% of revenue, product-level gross margins are in the mid-to-high 60s percent, and EBIT margins are in the low-to-mid single digits. It carries an option on higher-value applications in biofilm control, shelf-life extension and medical decontamination. Divesting the pool and spa brands in 2021 removed about EUR 5m of commodity-chemistry revenue, but it also removed about half of the 2019 carbon footprint. Since then, B2B food industry has become the growth engine, rising from about 56% to 59% of sales between FY2023 and FY2025.
Strategy
Stated strategy themes (paraphrased from company documents)
-
Refocus on enzymatic green chemistry and high value-added B2B. The pool and spa sale was explicitly framed as ending exposure to "classic chemistry" and concentrating on environmentally friendly, high value-added products and services (CEO, press release, March 2021). Since then, strong B2B growth has raised the share of high value-added sales (2024 Annual Report).
-
Biofilm leadership and international growth. The pool sale was intended to accelerate international expansion in the "fight against biofilms" and to fund Eezym (March 2021).
-
External growth. In October 2021 Realco mandated E-Spring Capital to acquire a B2B industrial food-hygiene company in a neighbouring country. A board member described an acquisition as an essential growth engine amid sector consolidation. No acquisition has been announced in the five years since.
-
Innovation pipeline. Nine projects were cited in 2021. The 2024 Annual Report describes two axes: disruptive new products, and incremental re-engineering. Named projects are Cold Cleaning, SuCoLib, SampleZym, CleanPack (terminated) and KillZym.
-
"People, Planet, Prosperity" sustainability framework. The company targets "healthy and virtuous organic growth" and maps its strategy to the UN SDGs (2, 3, 6, 8, 9, 13, 14, 15).
-
Organisational transformation. Holacracy-inspired shared governance is being rolled out step by step from 2024, with a "vision committee" and training investments.
Initiatives announced or advanced in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Type | Detail | Status | Source |
|---|---|---|---|---|
| KillZym / KillZyme | R&D, new product | Natural-ingredient biocide for the food industry to reduce the ecological footprint of disinfection and contribute to antimicrobial-resistance mitigation; partners ULiège (CIP), UCLouvain (LDRI), B12 Consulting (bio-informatics); funded via the Wagralim competitiveness cluster | Applications filed Mar and Sep 2024; kick-off at Realco on 2 April (2025, per lab start date); lab work from 2025 | 2024 Annual Report; LinkedIn |
| SuCoLib | R&D | Natural compounds plus enzymes against Listeria monocytogenes biofilms in the salmon industry; Walloon recoverable advances (30% fixed repayment 2026–2030; 70% variable at 3.53% of product turnover) | Research phase ended late 2025 | NBB FY2025 note 15; 2024 Annual Report |
| SampleZym | R&D | Enzymatic sampling method to detect microorganisms missed by classic swabbing; poster at the French Society of Microbiology national congress | In development | 2024 Annual Report |
| Cold Cleaning extension | Product | Low-temperature enzymatic formulas extended to new food, catering and retail ranges | Ongoing | 2024 Annual Report |
| Eco-formulation definition and LCAs | ESG, product | Objective definition of "eco-formulation" to score the whole portfolio; first product LCA (flagship food-industry product) with more planned | 2024 onwards | 2024 Annual Report |
| ERP modernisation | Operations | To streamline processes and support capacity growth | In progress | 2024 Annual Report |
| Undenatured alcohol licence | Regulatory, ESG | Become an approved holder of undenatured alcohol (target 2025) to eliminate suspected endocrine-disrupting denaturants | Target 2025; outcome not disclosed | 2024 Annual Report |
| Mobility policy and Akt for Wallonia mobility audit | ESG, cost | Formal business-travel policy from 2025 | 2,025 | 2024 Annual Report |
| EcoVadis | ESG | First submission in May 2026, silver medal | Completed | Company news (Jun 2026) |
| OneLife financing | Portfolio | Bridge convertible loan in Dec 2024; FY2025 write-down of EUR 1.25m | Ongoing exposure | 2024 Annual Report; NBB FY2025 |
Cost programmes
No formal cost-reduction programme with quantified targets has been disclosed. Margin protection measures include a tariff-revision process introduced to pass through raw-material, energy and automatic wage-indexation inflation (2024 Annual Report).
Medium-term financial targets and guidance
Not publicly disclosed. Realco issues no revenue, margin or EPS guidance.
The only quantified "growth" target identified concerns the associate OneLife: in 2021 it aimed for EUR 20m annual revenue by 2026 (La Libre). With FY2024 turnover of EUR 0.89m and a FY2025 loss of EUR 1.2m, this target will clearly not be met.
Non-financial 2030 targets include:
-
Scope 1+2 emissions −46% and Scope 3 −18% versus 2019;
-
25% of sales from Ecocert products;
-
50% recycled plastic in primary packaging;
-
zero aquatic-toxic detergents;
-
water intensity below 1 m³ per tonne produced.
Products & Services
Realco discloses about 230 active formulas (2024 Annual Report). Individual product SKU names, prices and launch years are largely not published. The catalogue below is organised by sector and expertise pole, using company-published descriptions. Pricing models are not publicly disclosed for any line.
Food industry
| Offering | Description and capabilities | Target customer | Launch / latest version | Source |
|---|---|---|---|---|
| Biofilm Expert Services (Biosafety pole) | Patented methodology to audit installations, then detect, eliminate and prevent biofilm contamination; combines enzymatic cleaning, which breaks the biofilm matrix so disinfection can reach the bacteria, with sampling and monitoring | Meat, dairy, beverage, ready-meal and plant-based processors | Methodology validated by research published Sep 2020; ongoing | Website; 2024 Annual Report; DH (2020) |
| Shelf-life extension programmes | Enzymatic cleaning protocols shown in the Biofilm Expert study to extend use-by dates by up to 100% (one customer example: 11 to 23 days on fresh burgers) | Fresh-food processors | 2020 onwards | Press page; website |
| Membrane filtration range and Performance Optimization Program | Products tailored to unit type and fouling, plus audit, treatment and monitoring, to raise filter throughput, cut cleaning, water and energy costs and extend membrane life | Dairy (whey, milk protein), beverage | Ongoing; filtration formulas being reformulated to exit aquatic-toxicity Category 3 by 2030 | Website; 2024 Annual Report |
| Cold-cleaning enzymatic formulas | Enzyme formulations effective at low temperature; energy savings for users; being extended to new ranges | Food industry, catering, retail | Commercialised since 2023; extended in 2024 | 2024 Annual Report |
| "Global & sustainable hygiene" range (Conscious / Essential Cleaning) | Full product range plus support to adopt hygiene solutions aligned with each sector's sustainability goals; "the right dose for controlled hygiene" | All B2B sectors | Ongoing | 2024 Annual Report; website |
| Water treatment packages | Enzymatic products that accelerate biodegradation of organic loads in wastewater; maintenance of water-treatment systems; tailored packages per installation | Food plants, kitchens, healthcare sites | Historic core activity since 1968 | Website; 2024 Annual Report |
| Resold non-enzymatic disinfectants | Complementary disinfectants Realco does not manufacture but supplies; denaturant control to be strengthened in 2026 | B2B customers | Ongoing | 2024 Annual Report |
Food services and retail
| Offering | Description | Target customer | Source |
|---|---|---|---|
| Enzymatic surface and floor cleaner-disinfectants | Liquid enzymatic products for floors, walls, worktops and epoxy; dosed at 0.5–1% in warm water (35–50°C) via Venturi dispensers; about 15 minutes contact time; claimed to prevent pipe clogging through continued enzyme action | Collective kitchens, schools, hospitals, butchers | Realco product sheets (2014) |
| Dishwashing products | Machine dishwashing range (about 4% of sales volume in 2024) | Restaurants, collective catering | 2024 Annual Report |
| Co-branding programmes | Development of Food Services through co-branding and long-term partnerships to raise the share of Ecocert-certified sales | Distributors, catering groups | 2024 Annual Report |
| Realco Academy, audit and technical support | Training, on-site follow-up, didactic materials, PPE guidance | All professional users | Website; 2024 Annual Report |
Health
| Offering | Description | Target customer | Source |
|---|---|---|---|
| Life Sciences Biosafety range | Hygiene and biofilm control products and services for pharmaceutical and cosmetics production; higher water-quality standards required | Pharma and cosmetics plants | 2024 Annual Report (range launched 2023) |
| OneLife medical range (via 33.85%-owned OneLife SA) | Biofilm detection (blue colouring of biofilm on instruments) plus enzymatic detergents that dissolve biofilm and bioburden on medical devices and hospital surfaces; ISO 13485-certified; also endoscope inspection equipment (borescopes) sold in Belgium | Hospitals, central sterile services, dental and animal care | DH (2013); Dealroom; 2024 Annual Report |
Home
| Offering | Description | Target customer | Source | — |
|---|---|---|---|---|
| Eezym (#homedetox) | Enzyme-based household cleaners from naturally derived renewable ingredients, Ecocert Greenlife "Ecodétergent" certified; multi-purpose cleaner and dish spray cited by customers; bottles 100% PCR since the 2024 relaunch; about EUR 1.0m sales in 2024 | Consumers via retail and DIY chains and webshop | Launched 2017; relaunched 2024 | L'Avenir (2017); 2024 Annual Report |
Discontinued or divested
| Offering | Status | Source |
|---|---|---|
| Splash (pool maintenance) and Zen (spa) | Sold to Manufacturas Gre SAU (Fluidra) on 14 Oct 2021; market leaders in Belgian retail pool and spa care; about EUR 5m turnover in 2020 | Press releases (Mar and Oct 2021) |
| CleanPack (pea-starch biopolymer doses) | Project terminated after partner PolyPea's bankruptcy (Oct 2024) | 2024 Annual Report |
Portfolio health metrics (2024 Annual Report)
-
No formula is classified CMR (carcinogenic, mutagenic or reprotoxic); the company has committed to exclude known and suspected endocrine disruptors.
-
91% of the detergent range is free of aquatic-toxicity classification; the target is zero toxic-classified detergents by 2030.
-
40 Ecocert-certified references in 2024 (5 in 2019), representing 19% of sales volume; the target is 25% by 2030.
-
About 20% of the portfolio consists of acid or alkaline solutions reserved for professional uses (filtration, dishwashing, descaling).
-
Two inhalation-classified formulas, used in closed circuits only, represent about 4% of sales volume.
-
15 new formulas were being launched in 2024 (+7% portfolio), and 30 of 230 formulas (13%) were re-engineered.
Product Portfolio
| Offering | Description | Target customer | Source | |
|---|---|---|---|---|
Eezym (#homedetox) | Enzyme-based household cleaners from naturally derived renewable ingredients, Ecocert Greenlife "Ecodétergent" certified; multi-purpose cleaner and dish spray cited by customers; bottles 100% PCR since the 2024 relaunch; about EUR 1.0m sales in 2024 | Consumers via retail and DIY chains and webshop | Launched 2017; relaunched 2024 | L'Avenir (2017); 2024 Annual Report |
Financial Detail
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Food industry revenue (EUR K) | 6,566 | 6,711 | 8,105 |
Food services and retail revenue (EUR K) | 3,229 | 3,765 | 3,280 |
Home revenue (EUR K) | 1,603 | 1,489 | 1,671 |
Health revenue (EUR K) | 285 | 449 | 736 |
Total turnover (EUR K) | 11,684 | 12,415 | 13,792 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment growth and mix (%)
| Segment growth and mix (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Food industry YoY growth (%) | — | 2.2 | 20.8 |
Food services YoY growth (%) | 23.3 | 16.6 | -12.9 |
Home YoY growth (%) | — | -7.1 | 12.2 |
Health YoY growth (%) | — | 57.6 | 63.8 |
Food industry share of turnover (%) | 56.2 | 54.1 | 58.8 |
Food services share of turnover (%) | 27.6 | 30.3 | 23.8 |
Home share of turnover (%) | 13.7 | 12.0 | 12.1 |
Health share of turnover (%) | 2.4 | 3.6 | 5.3 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Turnover (EUR K) | 13,621 | 9,723 | 11,684 | 12,415 | 13,792 |
Total operating income incl. other income and capitalised development (EUR K) | — | — | — | 13,434 | 14,714 |
Purchases and goods for resale (EUR K) | — | 3,517 | 4,233 | 4,181 | 4,360 |
Product gross profit = turnover − purchases (EUR K, analyst-calculated) | — | 6,206 | 7,451 | 8,234 | 9,433 |
Gross margin, NBB definition (EUR K) | — | 3,779 | 4,996 | 5,420 | 6,545 |
Services and other goods (EUR K) | — | — | — | 3,617 | 3,791 |
Personnel costs (EUR K) | 3,461 | 3,800 | 4,219 | 4,336 | 4,562 |
Depreciation and amortisation (EUR K) | — | — | — | 994 | 1,166 |
Operating result / EBIT (EUR K) | — | 189 | 207 | 265 | 781 |
EBITDA (EUR K) | 3,375 | 557 | 892 | 1,287 | 1,947 |
Financial income (EUR K) | — | — | — | 108 | 224 |
Financial charges incl. non-recurring (EUR K) | — | — | — | 238 | 1,795 |
Pre-tax result (EUR K) | — | — | — | 136 | -790 |
Income taxes (EUR K) | — | — | — | 6 | 6 |
Net result (EUR K) | 2,036 | 124 | 259 | 157 | -771 |
EPS basic, approximate (EUR, on about 643,610 shares) | 3.16 | 0.19 | 0.40 | 0.24 | -1.20 |
Dividend declared, total (EUR K) | — | — | — | 300 | 0 |
Dividend per share, approximate (EUR) | — | — | — | 0.47 | 0.00 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Turnover growth YoY (%) | — | -28.6 | 20.2 | 6.3 | 11.1 |
Product gross margin (%) | — | 63.8 | 63.8 | 66.3 | 68.4 |
Gross margin, NBB definition (% of turnover) | — | 38.9 | 42.8 | 43.7 | 47.5 |
EBITDA margin (%) | 24.8 | 5.7 | 7.6 | 10.4 | 14.1 |
Operating (EBIT) margin (%) | — | 1.9 | 1.8 | 2.1 | 5.7 |
Net margin (%) | 14.95 | 1.28 | 2.22 | 1.26 | -5.59 |
Personnel costs / turnover (%) | 25.41 | 39.08 | 36.11 | 34.93 | 33.08 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR K) | 13,356 | 17,390 | 17,321 | 16,831 | 15,685 |
Intangible assets (EUR K) | — | — | — | 404 | 697 |
Tangible assets (EUR K) | — | — | — | 8,248 | 7,582 |
Financial fixed assets (EUR K) | — | — | — | 2,810 | 1,539 |
Inventories (EUR K) | — | — | — | 1,719 | 1,569 |
Trade receivables (EUR K) | — | — | — | 2,507 | 2,482 |
Other receivables (EUR K) | — | — | — | 775 | 444 |
Cash and equivalents (EUR K) | 2,783 | 1,191 | 709 | 309 | 1,322 |
Long-term financial debt (EUR K) | — | — | — | 4,201 | 3,903 |
Short-term financial debt, current portion of LT debt (EUR K) | — | — | — | 778 | 718 |
Total financial debt (EUR K) | — | — | — | 4,979 | 4,621 |
Net financial debt (EUR K) | — | — | — | 4,669 | 3,299 |
Total liabilities excl. equity and provisions (EUR K) | 5,222 | 8,083 | 7,991 | 6,984 | 6,790 |
Provisions (EUR K) | — | — | — | 518 | 454 |
Shareholders' equity (EUR K) | 7,182 | 8,439 | 8,699 | 9,281 | 8,441 |
Goodwill (EUR K) | 0 | 0 | 0 | 0 | 0 |
Working capital = current assets − current liabilities (EUR K) | — | — | — | 2,585 | 3,005 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Capex: tangible + intangible + capitalised development, derived from fixed-asset notes (EUR K) | — | — | — | — | 792 |
Dividends paid in year (EUR K) | — | — | — | — | 300 |
Share buybacks (EUR K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (EUR K) | — | -1,592 | -482 | -399 | 1,013 |
Net financial debt repayment (EUR K) | — | — | — | — | 357 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on year-end equity (%) | 28.37 | 1.47 | 2.98 | 1.69 | -9.13 |
ROA on year-end assets (%) | — | 0.71 | 1.50 | 0.93 | -4.91 |
Pre-tax ROIC proxy = EBIT / (equity + net debt) (%) | — | — | — | 1.9 | 6.7 |
Current ratio (x) | — | — | — | 1.93 | 2.05 |
Financial debt / equity (x) | — | — | — | 0.54 | 0.55 |
Net debt / EBITDA (x) | — | — | — | 3.71 | 1.69 |
Interest coverage = EBIT / recurring financial charges (x) | — | — | — | 1.12 | 2.82 |
Asset turnover = turnover / year-end assets (x) | — | 0.56 | 0.67 | 0.74 | 0.88 |
Days sales outstanding (days) | — | — | — | 74 | 66 |
Days inventory outstanding on purchases (days) | — | — | — | 150 | 131 |
Days payables outstanding on purchases + services (days) | — | — | — | 57 | 52 |
Cash conversion cycle (days) | — | — | — | 167 | 145 |
Region / Country Details
| Region / country | Evidence | Source |
|---|---|---|
Belgium (home market) | Primary market; most sales occur in Belgium per aggregator descriptions; close to 50% of procurement spend is also Belgian | FMP profile; 2024 Annual Report |
France | French establishment (SIREN 507 486 637) registered since 2008; cited among export markets | Pappers; FMP |
Italy | Linked partner site Piramide Ambiente ("our expertise in Italy"); Italian-language detergent catalogues distributed via REPA. One third-party profile refers to "subsidiaries in the US and Italy", but no Italian participation of ≥10% appears in the NBB FY2025 participation list | Website; MTEC profile; NBB |
Spain, Germany, Eastern Europe | Cited export markets; multilingual REPA catalogues; participation in an industry event in Bucharest (ESE 2026, 11–12 March 2026) | FMP; LinkedIn |
Japan | Cited export market; one customer invoiced in yen | FMP; 2024 Annual Report (FX risk section) |
United States | Realzyme LLC (Springboro, Ohio), 75%-owned: FY2023 revenue USD 1.398m (+12.8%), net ordinary income USD 127k; FY2025 net income USD 179k, equity USD 382k. About 74% of Realzyme sales are Biofilm and Filtration ranges | 2024 Annual Report; NBB FY2025 |
Revenue by Region
| Metric | FY2024 |
|---|---|
OneLife sales in Belgium (EUR K) | 311 |
OneLife sales via European distributors (EUR K) | 269 |
OneLife export sales (EUR K) | 306 |
OneLife total turnover (EUR K) | 888 |
OneLife turnover (EUR K, read from 2024 Annual Report chart)
| OneLife turnover (EUR K, read from 2024 Annual Report chart) | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
OneLife turnover (EUR K) | 701 | 762 | 507 | 733 | 888 |
Margin Analysis (%) (FY2019–FY2025)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
Calendar-year share price change (%) | 25.00 | -11.20 | -13.96 | 9.95 | -11.90 | -16.22 | 21.29 |
Valuation Multiples
| Multiple | Realco |
|---|---|
Market capitalisation | About EUR 11.3m |
Enterprise value (market cap + net financial debt EUR 3.3m) | About EUR 14.6m |
P/E (FY2025) | Not meaningful (EPS −1.20) |
P/E (FY2024 EPS 0.24) | About 73x |
EV/EBITDA (FY2025 EBITDA EUR 1.95m) | About 7.5x (about 9.4x excluding EUR 402k capitalised development) |
EV/Sales (FY2025) | About 1.06x |
P/B (FY2025 equity EUR 8.44m) | About 1.34x |
Dividends & Capital Returns
| Metric | FY2024 | FY2025 |
|---|---|---|
Total dividend declared (EUR K) | 300 | 0 |
Debt Maturity Profile
| Maturity bucket | Amount (EUR K) |
|---|---|
Due within 1 year | 718 |
Due in 1–5 years (credit institutions 2,664; lease 95) | 2,759 |
Due after 5 years | 1,144 |
Total financial debt | 4,621 |
Analyst Conclusions
Management guidance and consensus
Management guidance: not publicly disclosed. Qualitative direction from the 2024 Annual Report and the 2021 press releases: continue B2B organic growth, invest in innovation and sustainability, seek external growth, and strengthen shared governance.
Consensus: none.
Bull case
-
Operating inflection is real. On a comparable perimeter, turnover compounded at about 12% over FY2022–FY2025. Product gross margin expanded about 460 bp to 68.4% after re-internalisation. Even excluding capitalised development, EBIT roughly doubled in FY2025. Continued food-industry growth (+20.8%) on a largely fixed cost base could take EBIT margins towards high single digits.
-
The OneLife overhang is largely provisioned. After the EUR 1.25m write-down, residual exposure is EUR 1.53m of book value. Realco also benefits commercially from OneLife as a customer: Health sales rose to EUR 736k. Any OneLife partnering or exit would be upside against a cleaned-up base.
-
The valuation is undemanding for a niche IP owner. At about 1.06x EV/Sales, about 7.5x EV/EBITDA and 1.34x P/B, the market pays little for the patent estate, the profitable US subsidiary (independently valued at USD 1.5m for 100% equity in 2023) or the pipeline. Deleveraging (net debt/EBITDA from 3.7x to 1.7x) restores capacity for bolt-on M&A or a resumed dividend.
Bear case
-
Underlying profitability remains thin and flattered. Before FY2025, EBIT never exceeded 2.1% of sales. FY2025 EBIT includes EUR 268k from a change in accounting policy, and the Food services decline (−12.9%) is unexplained.
-
Capital allocation and governance concerns. Cumulative investment in OneLife (EUR 1.65m to 2024, plus further conversions) has largely been written off against an unrealistic EUR 20m revenue target. The EUR 300k FY2024 dividend exceeded net income just before a loss year. The board is family-concentrated with no disclosed committees.
-
Structural scale and liquidity discount. At EUR 13.8m turnover, Realco competes against multinationals with service networks. Disclosure is minimal (no cash-flow statement, no shareholder percentages). Trading on Euronext Access is sporadic. The five-year share performance is about −15%, which limits re-rating potential.
Key catalysts and monitorables (next 12 months)
H1/FY2026 trading: whether Food industry growth persists and Food services stabilises. Look for the FY2026 results announcement around May 2027.
OneLife: further funding rounds, dilution, partnering, or additional write-downs.
Pipeline: SuCoLib commercialisation (royalty-style repayment signals revenue), KillZym regulatory pathway, SampleZym.
M&A: any announcement under the long-standing acquisition strategy.
Dividend policy: whether distributions resume once retained earnings (EUR −596k at end-2025) turn positive.
Governance: content of the June–July 2026 board changes; any formal committee structure.
ESG: progress on SBTi Scope 1+2, Ecocert share and recycled packaging; leverage of EcoVadis silver in corporate tenders.
Balance sheet: cash conversion, scheduled debt amortisation (EUR 718k in 2026) and SuCoLib repayments.
Analyst verdict
Realco is a credible but sub-scale specialist that has spent six years repairing itself. The 2020 fire forced three and a half years of subcontracting. The 2021 sale of the Splash and Zen pool brands removed a third of revenue and half of the carbon footprint. The company then rebuilt a modern, insured plant financed by indemnities, bank debt and Walloon subsidies. The FY2025 statutory accounts show that this repair is working at the operating level: record turnover of EUR 13.8m, product gross margin of 68%, EBIT of EUR 0.78m, and net debt down to EUR 3.3m (1.7x EBITDA). The technology is genuine: patented enzyme–biofilm formulations, a court-enforced IP position, and documented shelf-life benefits. It is also well aligned with food processors' safety, waste and decarbonisation agendas.
The investment case, however, is constrained by three factors that the market rightly discounts. First, the core remains marginally profitable once one strips out the newly capitalised development costs: underlying EBIT is about 3.7% of sales. Second, capital allocation has been uneven. Most of the money put into OneLife has been written off, the promised acquisition never materialised, and a dividend larger than profit was paid just before a loss. Third, governance and disclosure fall short of institutional standards. There is family control of the Chair, CEO and CFO roles, no published committees, no cash-flow statement, no shareholder register percentages and no analyst coverage. Liquidity on Euronext Access is minimal.
At about EUR 11m market cap (about 1.1x EV/Sales, about 1.3x book), the shares price in little growth. Upside depends on sustained double-digit food-industry growth, stabilisation of food services, no further OneLife drain, and visible commercialisation of the SuCoLib and KillZym pipeline. Investors with a long horizon and tolerance for illiquidity may find asymmetric value. For most institutional mandates, Realco remains a watch-list name until two consecutive years of clean, cash-backed profitability and improved governance disclosure are delivered.
DATA QUALITY & DISCREPANCY NOTES
-
FY2024 net result: EUR 156.7k (statutory, NBB / Companyweb) versus EUR 263.9k (2024 Annual Report). The difference is a EUR 107.2k withdrawal from untaxed reserves.
-
FY2025 revenue: EUR 13.79m turnover (NBB) versus EUR 14.71m "revenue" (Stockanalysis, equal to total operating income) versus EUR 14.19m trailing-twelve-month (Yahoo).
-
FY2024 total assets: EUR 16,830.8k (NBB) versus EUR 16,829.1k (2024 Annual Report); immaterial.
-
Share count: about 643,610 (Simply Wall St) versus 635,700 (FMP, April 2024).
-
EBITDA definitions: Signumi (FY2022–FY2024) versus analyst EBIT + D&A (FY2025); third-party EBITDA of EUR 0.53m (MarketInOut) uses a different basis.
-
FY2021 figures: derived from Boursorama ratios and Signumi year-on-year changes; approximate.
-
FY2023 segment revenue: derived from FY2024 growth rates in the 2024 Annual Report; reconciles to the reported total.
-
Erroneous aggregator profiles: Twelve Data (real estate description) and Tracxn (bacteriophage company, 113 employees) misidentify the company and were disregarded.
-
Signed FY2025 management report: published as an image-only PDF and not machine-readable. FY2025 management commentary (drivers of the Food services decline, outlook) therefore could not be extracted.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Director | Represented by | Role | Mandate | Background (public information) | Source |
|---|---|---|---|---|---|
Oxygen SA | Gordon Blackman | Chairman | 28 May 2024 – AGM 2026 | Acquired Realco in 1991; former CEO; reference shareholder through Oxygen SA | NBB FY2025; investor page |
D2G SRL | George Blackman | Managing director (administrateur délégué) and CEO | 30 May 2023 – AGM 2026 | CEO since 2017 (own statement, 2021 press release); on the board since about 2013 (Investing.com) | NBB; press release |
Dare Consulting SRL | Frédéric Tiberghien | Director | 25 May 2024 – AGM 2026 | On the board since 2021; spokesperson on M&A strategy in 2021 | NBB; press release (Oct 2021) |
Sparaxis SA | Jean-Luc Nondonfaz | Director | 28 May 2024 – AGM 2026 | Represents Sparaxis SA (Liège-based investment company) | NBB |
Nomainvest SA | Bernard Jolly | Director | 27 May 2025 – AGM 2027 | Represents shareholder Nomainvest SA | NBB; investor page |
Xavier Sinéchal | — | Director | 28 May 2024 – AGM 2026 | Director since about 2013 | NBB; Investing.com |
Victoria Blackman | — | Director (also CFO since 2025) | 27 May 2025 – AGM 2027 | Family member; joined as CFO in 2025 | NBB; 2024 Annual Report |
Nathalie Guillaume | — | Director | 27 May 2025 – AGM 2027 | Joined in 2024; affiliated with Danone (per company announcement) | NBB; company news (Jul 2024) |
Aline Le Clef | — | Director | 27 May 2025 – AGM 2027 | Joined in 2024; affiliated with Sodexo (per company announcement) | NBB; company news (Jul 2024) |
Executive Leadership Team
| Name | Function | Notes |
|---|---|---|
George Blackman | CEO | Also managing director via D2G SRL |
Victoria Blackman | CFO | Joined in 2025 |
Sandrine Antoniou | People Partner | Leads the shift to holacracy-inspired shared governance |
Thibault Wauters | Food & Beverage North | Sales lead, northern region |
Laurent Paul | Food & Beverage South | Sales lead, southern region |
Tania Florent | Food Services | — |
Luk Van den Berghe | B2C (Eezym) | — |
Valentine Neirynck | Marketing & Communication | Also press contact |
Sébastien Fastrez | Research & Development | Named partner in the KillZyme project |
Philippe Demyttenaere | Operations | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
3 Jul 2024 | Aline Le Clef and Nathalie Guillaume join the board | Board evaluation in 2023 led to recruitment of profiles from customer-adjacent sectors (catering, food) |
| 2025 | Victoria Blackman appointed CFO | Strengthens female representation in governance (2024 Annual Report) |
27 May 2025 | AGM: appointments and renewals to 2027 (V. Blackman, N. Guillaume, A. Le Clef, Nomainvest/B. Jolly); Deloitte appointed auditor to 2028 | NBB FY2025 |
26 May 2026 | AGM: several mandates expired (Oxygen, D2G, Dare Consulting, Sparaxis, X. Sinéchal) | Investor page; Companyweb |
Dec 2021 | Koen Billet becomes CEO of OneLife (associate) | La Libre |
Major Shareholders
| Holder | Nature |
|---|---|
Oxygen SA | Holding vehicle of Gordon Blackman (Chairman) |
Nomainvest SA (Eupen) | Investor; board seat |
WE Environnement S.A. | Analyst inference: likely the environmental investment vehicle of Wallonie Entreprendre, successor of SRIW, Realco's long-standing public shareholder that supported the company after the 2020 fire (unconfirmed) |
Founding shareholders | Family and founders |
Free float (Euronext Access) | Public |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning versus Realco |
|---|---|---|
Food industry hygiene (CIP, open-plant cleaning, membrane cleaning) | Ecolab (US) | Global leader in food and beverage hygiene with service-intensive model; scale, global accounts, enzymatic membrane cleaners within a broad portfolio |
Food industry hygiene | Diversey (now part of Solenis, US) | Major food and beverage and institutional hygiene supplier |
Food industry hygiene | Kersia (France) | Food-safety and biosecurity specialist from farm to fork; direct overlap in biofilm and food-processing hygiene |
Food industry hygiene | Christeyns (Belgium) | Belgian family-owned hygiene group; food hygiene and professional laundry; local competitor |
Enzymes / biosolutions | Novonesis (Denmark) | Leading enzyme producer; potential supplier and competitor in biological cleaning and wastewater biosolutions |
Food services / institutional | Ecolab, Diversey/Solenis, Christeyns, Orapi (France) | Broad institutional chemical ranges; Realco differentiates on enzymatic, pH-neutral, worker-safe formulations |
Medical device decontamination (OneLife) | Steris (US/Ireland); Ruhof (US); Dr. Weigert (Germany) | Established enzymatic instrument-detergent suppliers with hospital channel scale |
Home eco-cleaning (Eezym) | Ecover / Method (SC Johnson); Frosch (Werner & Mertz); L'Arbre Vert (France) | Mass-market eco brands with retail scale; Eezym differentiates on enzymes and Ecocert certification but is sub-scale (about EUR 1.0m in 2024) |
Wastewater bio-treatment | Novonesis and specialty biological-product suppliers | Overlap in grease and organic-load degradation products |
Competitor Detail
| Metric | Realco FY2025 |
|---|---|
Revenue | EUR 13.8m |
Revenue growth | +11.1% |
EBIT margin | 5.7% (about 3.7% excluding capitalised development) |
Product gross margin | 68.4% (turnover − purchases) |
R&D intensity | Not disclosed (third-party claim >15%) |
Recent Developments
Realco is a micro-cap on Euronext Access with sparse disclosure. All identified items are listed below, including smaller ones.



